Every 10-Q that Paysign, Inc. (PAYS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PAYS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PAYS filings page.
Paysign, Inc. reported sharp growth for the three and six months ended June 30, 2026, with total revenues of $28,252,071 for the quarter and $56,290,495 year-to-date, driven mainly by plasma and pharma patient affordability programs.
Quarterly plasma revenue rose to $13,040,540 and pharma revenue to $14,649,133, supporting gross margin expansion to 63.3%. Net income increased to $6,756,537 for the quarter and $12,195,455 for six months, reflecting operating leverage, higher interest income and a $990,000 fair value gain from eliminating the Gamma contingent consideration liability.
The company ended June 30, 2026 with total assets of $316,989,606, including cash of $27,372,858 and restricted cash of $149,109,681, against customer card funding liabilities of $148,196,011. Management highlights accelerated growth in pharma claim volumes and continues to invest in technology, compliance, customer service and sales to support expansion.
Paysign, Inc. delivered a very strong first quarter of 2026, with revenue of $28,038,424, up 50.8% from $18,598,149 a year earlier. Growth was driven by plasma revenue rising to $11,748,611 and pharma revenue to $15,679,452.
Net income more than doubled to $5,438,918 from $2,586,100, lifting net margin to 19.4% from 13.9%. Diluted EPS increased to $0.09 from $0.05. Adjusted EBITDA rose to $10,588,294, with Adjusted EBITDA margin expanding to 37.8% from 26.7%.
Gross dollar volume loaded on cards increased to $514 million from $407 million, reflecting higher activity across programs. Cash (excluding restricted cash) stood at $20,545,119, and management believes this, together with forecast cash flows, will sustain operations for the next twenty‑four months.
Paysign, Inc. reported strong Q3 2025 results. Revenue was $21,596,478 (up 41.6% year over year), led by pharma programs at $7,920,604 (up 141.9%) and plasma at $12,860,478 (up 12.4%). Gross margin improved to 56.3%.
Net income was $2,215,135 and diluted EPS was $0.04. Operating income rose to $1,581,951, while interest income contributed $663,666. The effective tax rate was 1.36%. Year-to-date, revenue reached $59,272,980 (up 38.6%) and net income was $6,188,996 (up 153.3%), reflecting higher pharma activity and added plasma centers.
Cash was $7,529,047 with total cash and restricted cash of $118,551,886 at period end. Accounts receivable increased to $49,644,417. The company closed the Gamma Innovation acquisition on March 19, 2025 for $15,558,637, adding $11,071,000 of identifiable intangibles and $4,487,637 of goodwill. Shares outstanding were 55,042,888 as of November 6, 2025.
Key results (Q2 2025): Total revenues $19,078,353; gross profit $11,755,165; net income $1,387,761; gross margin 61.6%.
Six months YTD: Revenues $37,676,502; net income $3,973,861; gross margin 62.2%. Total assets $193,896,201; total liabilities $151,688,242; cash and restricted cash $113,913,123.
Drivers and transactions: Revenue growth driven by pharma industry (+$5,079,005; +189.9% Q2; +$11,309,014; +223.3% YTD). Plasma revenue declined (-4.7% Q2; -6.9% YTD). On March 19, 2025 Paysign acquired Gamma Innovation LLC: preliminary purchase consideration $15,558,637; identifiable intangible assets $11,071,000; goodwill $4,487,637; earn-out contingent consideration revised to $990,000.